eJHaemBone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes.
Stephen T. Oh +17 more
doaj +1 more source
Targeting Ref-1/APE1 Pathway Inhibition in Pancreatic Cancer Using APX3330 for Clinical Trials [PDF]
, 2016 poster abstractPancreatic ductal adenocarcinoma is the 4th leading cause of cancer-related mortality in the US. Most patients present with advanced disease and ~95% die within five years, most surviving under six months.
Fishel, Melissa L. +6 more
core
Ruxolitinib Suppresses Interferon‐γ‐Induced JAK/STAT Activation in Oral Keratinocytes
Clinical and Experimental Dental Research, Volume 12, Issue 1, February 2026.ABSTRACT Objectives The Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway plays a crucial role in oral inflammatory diseases such as oral lichen planus (OLP) and periodontitis. Interferon‐gamma (IFN‐γ) is a cytokine that activates the JAK/STAT pathway.
Kim N. Stolte +4 more
wiley +1 more source
Suppressive CD8+ T‐Cells Are Key Cellular Mediators of Extracorporeal Photopheresis
Journal of Clinical Apheresis, Volume 41, Issue 1, February 2026.ABSTRACT Extracorporeal photopheresis (ECP) is a widely utilized immunomodulatory procedure with an incompletely defined mechanism. In graft‐versus‐host disease (GvHD) and transplant rejection, ECP is thought to induce immune tolerance by increasing regulatory CD4+ T‐cells, whereas in cutaneous T cell lymphoa it may enhance dendritic cell–mediated ...
Kai J. Rogers +7 more
wiley +1 more source
Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib [PDF]
Justin Arnall +2 more
openalex +1 more source
Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.ABSTRACT Background Sarcopenic obesity, where excess body fat coexists with reduced muscle mass and function, is becoming increasingly common in ageing populations and contributes to poor physical and metabolic health. Although adipose tissue–secreted factors are implicated in muscle decline, the specific mechanisms remain unclear.
Joshua M. J. Price +8 more
wiley +1 more source
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo [PDF]
Connie Kang
openalex +1 more source
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche
, 2020 Luigi Marino +11 more
openalex +1 more source
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) [PDF]
, 2018 Nikolas von Bubnoff +7 more
openalex +1 more source
A Case of Trichodysplasia Spinulosa Related to Ruxolitinib Treated Successfully with Oral Acitretin [PDF]
, 2023 Priscilla Rosa-Nieves +5 more
openalex +1 more source